Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: Past, present and future

Jérôme Dumortier, Olivier Boillot, Jean-Yves Scoazec

Abstract

Hepatitis C virus (HCV)-related liver disease, including cirrhosis and hepatocellular carcinoma is the main indication for liver transplantation (LT) worldwide. Post-transplant HCV re-infection is almost universal and results in accelerated progression from acute hepatitis to chronic hepatitis, and liver cirrhosis. Comprehension and treatment of recurrent HCV infection after LT have been major issues for all transplant hepatologists and transplant surgeons for the last decades. The aim of this paper is to review the evolution of our knowledge on the natural history of HCV recurrence after LT, including risk factors for disease progression, and antiviral therapy. We will focus our attention on possible ways (present and future) to improve the final long-term results of LT for HCV-related liver disease.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Hepatitis C; Liver transplantation; Recurrence; Fibrosis; Treatment

INTRODUCTION

Hepatitis C virus (HCV) has been estimated to infect 170 million people worldwide[1]. Liver disease due to HCV, including cirrhosis and hepatocellular carcinoma (HCC) is the main indication for liver transplantation (LT)[2,3]. Post-transplant HCV re-infection of the graft is reported to be universal and often results in accelerated progression from acute hepatitis to chronic hepatitis, and liver cirrhosis. Comprehension and treatment of recurrent HCV infection after LT have been major issues for all transplant hepatologists and transplant surgeons for the last 25 years. This is illustrated by the significant number of published papers in this field to date (1050 references in PubMed up to September 2013). The aim of this paper is to review the evolution of our knowledge on the natural history of HCV recurrence after LT including risk factors for disease progression, and antiviral therapy. We will focus our attention on possible ways (present and future)
to improve the final long-term results of LT for HCV-related liver disease.

**NATURAL HISTORY OF HCV RECURRENCE AFTER LT**

Recurrence of HCV infection after LT is universal, however, the natural history of hepatitis C on the liver graft is variable. It must be pointed out that the evaluation of recurrent hepatitis C has been described from liver biopsy, which is the cornerstone of clinical management of patients in daily practice. Nevertheless, differentiation of recurrent hepatitis C from acute cellular rejection can be difficult. Regev et al. demonstrated, from 105 cases blindly reviewed by 5 pathologists, that histological distinction between recurrent hepatitis C and acute rejection had low interobserver and intraobserver agreement rates, and hence showed low reliability. It has been suggested that transient elastography may provide good accuracy in identifying patients with severe fibrosis, better than non-invasive indices based on clinico-serological parameters, in LT recipients.

Histological recurrence is observed in 80% of HCV-infected patients within 5 years after LT. It is well known that liver disease caused by HCV infection progresses more rapidly in immunosuppressed than in immunocompetent individuals, and chronic HCV infection leads to cirrhosis in up to 20%-30% of individuals only five years after LT. In addition, the natural history of HCV recurrent cirrhosis is also accelerated after LT. The rate of decompensation is > 40% at 1 year and > 70% at 3 years in LT recipients vs < 5% and < 10%, respectively, in immunocompetent patients. The rate of progression from decompensation to death is also accelerated, with a 3-year survival of < 10% following the first decompensation vs > 60% in immunocompetent patients. Therefore, long-term graft and patient survival is significantly reduced in patients undergoing LT for HCV-related disease as compared to other indications. Disease progression (i.e., fibrosis progression) depends on a large number of variables, including host, donor, viral, and external factors. Interestingly, early post-LT (1-year) liver biopsy has great prognostic value and must be performed in every LT recipient. The 5-year probability of graft cirrhosis is associated with the severity of necroinflammatory activity of recurrent hepatitis C on the liver graft at 12 months. Similarly, the graft survival is significantly impaired in recipients with early HCV recurrence and fibrosis stage 3 and 4 at 1 year after LT.

Recurrent HCV-related liver disease after LT begins with a first phase of acute hepatitis and thereafter can have two distinct clinical and histological patterns. The first one is the most frequent and is the same as that described in non-transplant, or non immuno-compromised patients, and is characterized by the progression from chronic hepatitis to cirrhosis. Earlier onset of biochemical hepatitis and persistently elevated serum transaminases are associated with more rapid progression of fibrosis. The second type of recurrent hepatitis C after LT is specific for immunosuppressed patients (including HIV-positive patients and organ-transplanted patients, or both), and has been described as fibrosing cholestatic hepatitis (FCH). FCH has been observed in the context of hepatitis B virus or HCV infection and is characterized by rapid and extensive dense portal fibrosis and cholestasis leading to an inexorable deterioration in liver function. Estimates of HCV-related FCH frequency after LT range from 2%-14% vs < 5% and < 10%, respectively, in non-transplant, or non immuno-compromised patients. It has been hypothesized that FCH could be related to direct viral cytotoxicity after immune escape, associated with a deviation from a Th1 helper type intrahepatic cytokine response to a T helper 2 type response. As its prognosis is very poor (50% of patients die), predicting the onset of FCH and defining the patients at risk of developing this severe complication is a major goal. It has been suggested that FCH could be associated with older donor, corticosteroid treatment for acute rejection, stable quasispecies variants of HCV, earlier recurrence of HCV infection, higher HCV viral load, unfavorable recipient IL-28B polymorphism, and lower levels of immunosuppressive medications. Retransplantation for this specific complication remains controversial regarding its usual poor outcome.

Besides FCH, many reports have identified a large number of pre-transplant and post-transplant factors associated with more rapid progression of fibrosis, without taking into account antiviral treatment. The vast majority of these studies were retrospective, and this can be explained by the necessity to have mid- and long-term (5- or 10-year) evaluation of the liver graft. Donor features are major non-viral factors which are strongly associated with fibrosis progression. Older age, liver steatosis and diabetes mellitus are all deleterious. Donor age is probably the most relevant factor, but significant cut-offs (defining “old” donor) range from 33 to 50 years old. In addition, hepatitis C recurrence after LT from a donor older than 60 years could be a major factor in female recipients compared to male recipients. During the past 20 years, donor age has considerably increased (mean age in France was 53.2 in 2012, with 42% of the donors over 60, from the annual report of French Agence de la Biomedecine) and the selection of young donors for HCV recipients is questionable. The role of recipient age is still debated. Selzner et al. evaluated the role of donor and recipient age in transplantation/ischemia-reperfusion injury and short- and long-term graft and patient survival in a large population of 822 LT recipients. The HCV patients who were ≥ 50 years old and who were transplanted with an older graft (≥ 60 years) had significantly reduced 3- and 5-year graft survival. Interestingly, the use of HCV-positive donors has been reported not to alter the outcome after LT, and this is a way to enhance the number of available liver grafts. Recently, it has been suggested that the use of HCV-positive liver grafts from donors ≥ 45 years could be associated with more advanced fibrosis. At the time of LT, it has been suggested that prolonged cold and/or warm ischemia times
could negatively impact graft and patient survival\textsuperscript{[42]}. Some recipient characteristics also have a significant impact on HCV recurrence after LT. The reported impact of IL-28B genotypes (donor and recipient) on progression to cirrhosis after hepatitis C recurrence has been inconsistent\textsuperscript{[43]}. Reactivation of herpes group viruses [cytomegalovirus (CMV) and human herpes virus-6 (HHV-6)] may play a role in HCV recurrence after LT. Some reports have suggested that herpes virus infection could accelerate fibrosis progression\textsuperscript{[44,45]}. Recently, a retrospective study of 347 first LT recipients showed that CMV infection was associated with an increased risk of fibrosis stage $\geq 2$ and inflammation grade $\geq 2$\textsuperscript{[46]}. However, the widespread use of highly effective CMV prophylaxis regimens has probably reduced any potential effect of herpes virus reactivation on recurrent hepatitis C during the last decade. The risk of de novo diabetes mellitus after LT is increased in patients with HCV infection, especially in patients treated with tacrolimus (Tac)\textsuperscript{[47]}, and the presence of diabetes is associated with more rapid fibrosis progression\textsuperscript{[48]}. Similarly, alcohol consumption after LT also acts as co-factor and accelerates fibrosis progression in HCV patients\textsuperscript{[49]}. Some studies have suggested that HLA class I and II matching could increase fibrosis progression, without interfering with rejection\textsuperscript{[50,51]}. The prevalence of cryoglobulinemia is about 15%-20% in patients with end-stage HCV-related liver disease and almost 30% in LT recipients with recurrent hepatitis C. This has been found to be associated with reduced graft survival from more severe HCV recurrence and increased incidence of hepatic artery thrombosis\textsuperscript{[52-54]}. In summary, regarding the potential deleterious effect of all of these donor/recipient characteristics, from which a vast majority is not modifiable, the use a non steatotic liver graft from a young donor (< 50 years) could be recommended to reduce cold ischemia time, and to actively prevent CMV reactivation or primo-infection in each case of HCV LT recipient.

In addition to donor/recipient characteristics, the second major factor which can modify the natural history of recurrent hepatitis C after LT is HCV itself. First of all, higher HCV RNA levels (in serum and/or liver) at the time of LT are associated with increased risk of progression to cirrhosis, graft loss, and death\textsuperscript{[55,56]}; higher viral load in the early post-transplant period has also been associated with more rapid progression\textsuperscript{[57]}. The data on the relationship between HCV genotype and recurrent hepatitis C infection are more conflicting, and the impact of response to antiviral treatment induces major interferences. Nevertheless, genotypes 1b and 4 could be associated with more severe recurrent hepatitis C\textsuperscript{[13,58-61]}. During the last decade, human immunodeficiency virus (HIV)-HCV co-infection has emerged as a new indication for LT because of the major progress in the treatment of HIV infection. Duclus-Vallée et al\textsuperscript{[53]} first compared the survival and severity of recurrent HCV infection after LT in 35 HIV-HCV-co-infected and 44 HCV-monoinfected patients. The 2-year and 5-year survival rates were significantly reduced in co-infected patients: 73% and 51% vs 91% and 81% in monoinfected patients, respectively. The progression of fibrosis was significantly higher in the co-infected group. Therefore, improvement of prognosis in this specific indication is a major challenging issue for LT hepatologists.

Finally, the third goal in the field of transplantation is the impact of the immunosuppressive regimen on the severity of HCV recurrence. The effects of steroids on recurrent hepatitis C are complex. High-dose intravenous steroid boluses for acute rejection lead to a significant increase in HCV viral load and are associated with more rapid progression of recurrent hepatitis C\textsuperscript{[55]}. In addition, adjuvant antibody therapy (anti-thymocyte globulins, OKT3) for steroid-resistant rejection may be associated with more rapid progression to severe fibrosis\textsuperscript{[56,64]}. More recent data suggest that maintaining low-dose steroids over a long period could have beneficial effects on the progression of recurrent hepatitis C\textsuperscript{[65-67]} and the steroid-free regimen did not show an advantage in HCV recurrence\textsuperscript{[68]}. Similarly, the long-term use of azathioprine as part of maintenance immunosuppression therapy may be beneficial\textsuperscript{[20,69,70]}. The role of calcineurin inhibitors (CNIs), Tac and cyclosporine (CsA), on the severity of recurrent hepatitis C after LT is highly controversial. CsA might offer potential advantages over Tac. First, CsA directly suppresses HCV replication \textit{in vitro} by binding to cyclophilin B and inhibiting HCV RNA polymerase\textsuperscript{[70]}. Moreover, Tac, but not CsA, indirectly enhances HCV replication \textit{in vitro} through inhibition of phosphorylation and nuclear translocation of STAT-1, thereby blocking interferon signaling pathways\textsuperscript{[71]}. These experimental data could explain the findings of some retrospective studies which showed lower progression of fibrosis in patients receiving CsA instead of Tac\textsuperscript{[32,69,72]}. Nevertheless, several prospective randomized controlled studies comparing CsA and Tac as primary immunosuppressive drugs in HCV LT recipients have observed no differences in liver fibrosis and graft or patient survival\textsuperscript{[53-76]}. These results must be interpreted with caution since all endpoints measurement were probably too premature (< 5 years) to reach clinical relevance, especially in patients who received antiviral treatment. The influence of mTOR inhibitors requires further attention, since their inhibitory effects on transforming growth factor β and procollagen will delay liver graft fibrosis in LT patients with recurrent hepatitis C\textsuperscript{[77]}. In summary, regarding the lack of evidence regarding the potential role of immunosuppressive regimens on HCV recurrence after LT, it is recommended that the use of high doses of steroids and/or anti-thymocyte globulins or OKT3 for the treatment of acute rejection should be avoided.

**TREATMENT OF HCV RECURRENCE AFTER LT: PAST AND PRESENT**

The available evidence suggests that the best way to improve long-term outcome after LT for HCV-related...
liver disease is to cure HCV infection. For this purpose, three different strategies have been evaluated: (1) antiviral treatment before LT; (2) early antiviral (pre-emptive) treatment after LT; and (3) antiviral treatment at the time of biopsy-proven recurrent hepatitis C on liver graft. The majority of relevant data concerns antiviral combination therapy using pegylated alpha-interferon (PegIFN) and ribavirin (RBV).

The limits of antiviral treatment in patients awaiting LT include reduced efficacy in cirrhotic patients, the necessity to maintain the treatment for a relatively long period of time (in case of virological response), from 6 to 12 mo, problems in achieving full doses of PegIFN and RBV due to side effects (mainly hematological), and the risk of severe, sometimes lethal, complications (mainly infectious), especially in patients with decompensated cirrhosis[79]. The best candidates for therapy are Child-Pugh class A patients, with a relatively long expected time before LT (patients with HCC), especially in patients with a non-1 genotype, and the treatment should be maintained only in the case of early (or rapid) virological response[79].

The first generation direct acting antivirals (DAA), telaprevir and boceprevir, have not dramatically modified this algorithm, as better efficacy is counterbalanced by the high risk of severe infectious events in compensated cirrhotic patients[80]. Similarly, early (first month post-LT) pre-emptive antiviral treatment is usually not feasible and associated with poor hematological tolerance[81-83]. As a result, the vast majority of patients receive antiviral therapy when recurrent HCV hepatitis on liver graft is established, usually at least one year after LT. With PegIFN and RBV, the reported rate of viral clearance ranged from 20%-48%[84-90]. Factors associated with lower response when compared to non-LT patients include high viral load and high prevalence of genotype 1. Older donor age may also hinder the success of post-transplantation antiviral therapy[90-92]. Moreover, dose reduction and discontinuation of treatment were common in all studies (approximately 75% and 25%, respectively), due to adverse events and possibly represented the most important obstacles to attainment of viral clearance[86]. Interestingly, RBV dose reduction due to renal impairment probably has lower clinical impact as efficient plasma RBV concentrations can be obtained[97]. In addition, acute rejection often occurred during treatment (especially when protocol biopsies were performed[98]), which can induce graft dysfunction, and in some rare cases, graft failure and patient death[99]. Finally, it has been suggested that CsA may increase the antiviral effect of interferon-based therapy, when compared to Tac, by reducing the rate of relapse after an end-of treatment viral clearance[92,93,95,96]. The use of telaprevir and boceprevir after LT is a challenge, due to potential toxicity and drug-drug interactions with CNI8[100]. The first experience from 9 patients suggested that telaprevir-based triple therapy could be highly effective in LT patients, and that drug-drug interactions between telaprevir and immunosuppressants could be handled appropriately by the close monitoring of trough levels and adequate dose adjustments[103]. Further experience has recently been reported in a US cohort of 60 patients and in a French cohort of 37 patients[104,105]. In the French study, the end of treatment virological response rate was 72% in the boceprevir group and 40% in the telaprevir group[103]. When used with boceprevir, CsA dose was reduced by 36% and Tac dose by 78% when used with telaprevir, CsA dose was reduced by 48% and Tac dose was reduced by 95%. Infections occurred in 27% of patients, with a fatal outcome in one third. The most common adverse effect was anemia (92%), treated with erythropoietin and/or RBV dose reduction; 35% of the patients received red blood cell transfusions. These preliminary results suggest that first generation triple therapy is effective in LT recipients, particularly after failure of previous treatment, but is associated with poor tolerance. In the US cohort, according to an intention-to-treat analysis, 14 of 21 telaprevir-treated patients (67%) and 10 of 22 patients who received boceprevir (45%) achieved undetectable HCV RNA at week 24 without viral breakthrough at the last follow-up[104]. These contradictory results are probably related to patient-related differences as these two cohorts report preliminary experiences in an open-label design.

The beneficial effect of antiviral treatment and viral clearance on liver fibrosis and survival is intuitive and has been suggested by a randomized controlled study[98] and some uncontrolled studies[106-111]. Nevertheless, a lack of impact of HCV eradication on liver fibrosis in some other studies has also been reported[112-116]. This might be related to (1) an insufficient statistical power due to a small number of cases; (2) a too short period of follow-up (12-18 mo), because fibrosis improvement was probably delayed; (3) the inability of the fibrosis score to show mild improvement; and (4) interferences from other determinants of fibrosis than chronic viral hepatitis in some cases (rejection, biliary complications, ...). On the other hand, it has recently been suggested that maintenance antiviral treatment might slow fibrosis progression, even in cases of persistent HCV infection[111,117].

The ultimate treatment of recurrent HCV-related cirrhosis after LT is retransplantation. A number of studies have reported poor overall survival after retransplantation for this specific indication[118-120]. Although the decision to relist these patients can be difficult, a score could help to select candidates with the best potential outcome. Recently, a score which includes donor age, serum creatinine, international normalized ratio (INR) and serum albumin at the second transplantation, recipient age at the first transplantation, and the interval between first and second transplantations, has been proposed, and requires further evaluation[121].

**TREATMENT AND PREVENTION OF HCV RECURRENT AFTER LT: FUTURE PERSPECTIVES**

As LT is the ultimate step in the natural history of HCV
infection, major advances in antiviral treatment would probably dramatically change the management of LT recipients in daily practice in the next decade.

The next and promising step in antiviral therapy will be the use of second generation DAA, before and after LT, with the aim of obtaining viral eradication in more than 90% of cases, in both naïve patients and non-responders to previous therapy infected with all genotypes. Nevertheless, the second generation DAA, which have recently been submitted for registration (sofosbuvir and simeprevir) still need to be combined with PegIFN and RBV in patients infected with HCV genotype 1\[126\]. IFN-free regimens will be the ultimate step for future therapies consisting of combinations of novel DAA which are under investigation, such as daclatasvir or asunaprevir\[126,127\]. The good tolerance and lack of clinically apparent drug-drug interactions with CNIIs make these new DAA very attractive for future use in LT recipients\[127,128\]. The first case of successful IFN-free therapy (sofosbuvir and daclatasvir) in the setting of FCH has already been reported\[127\].

As the use of PegIFN, RBV and new DAA may be limited by resistance, adverse effects, and high costs, the development of new alternative preventive and/or therapeutic antiviral strategies is highly relevant. For example, HCV entry into hepatocytes is required for initiation, spread, and maintenance of infection, and could be the target of novel drugs, such as neutralizing antibodies for HCV envelope glycoproteins, blocking antibodies specific for host factors, or small molecular compounds against host factors or viral proteins\[129-137\]. Such strategies would be highly effective in the field of LT in order to prevent graft infection, and could be associated with other antiviral therapies.

Finally, emerging HCV treatments will impact on morbidity and mortality, and therefore, candidates for LT (presenting with HCC and/or decompensated cirrhosis) might significantly decrease during the next decades. Deuffic-Burban et al\[138\] recently simulated the progression of yearly-HCV-infected cohorts from the beginning of the epidemic and calculated 2013-2022 candidates for LT up to 2022 without and with therapies, in France. Overall, current treatment would enable an 88% and 42% reduction in the gap between LT and HCC and decompensated cirrhosis candidates, respectively. Interestingly, although HCV infection is treated with the same therapies in different countries, the effects of these therapies on morbidity and mortality vary significantly, suggesting that there is a need for public health policies based on population-guided therapy, in addition to common guidelines based on virological response-guided therapy\[139\].

In conclusion, regarding current major progress in HCV treatment, we hope that HCV-related liver disease will become a marginal indication for LT in one or two decades. Thus, as an important proportion of HCV patients are unaware of their condition, it is necessary to define an innovative public health policy to improve HCV screening, which is the only way of allowing non-tested HCV patients access to therapy before they develop advanced liver disease.

REFERENCES

1 Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47 [PMID: 10847128]
2 Adam R, McMaster F, O’Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Benenguer J, Jacke D, Moreno Gonzalez E. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-1243 [PMID: 14625822 DOI: 10.1016/j.lts.2003.09.018]
3 Merion RM. Current status and future of liver transplantation. Semin Liver Dis 2010; 30: 411-421 [PMID: 20960380 DOI: 10.1055/s-0030-1267541]
4 Regov A, Molina E, Moura R, Bejarano PA, Khaled A, Ruiz P, Arheart K, Berho M, Drachenberg CB, Mendez P, O’Brien C, Jeffers L, Tzakis A, Schiff ER. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10: 1233-1239 [PMID: 15376303 DOI: 10.1002/lt.20245]
5 Corradi F, Piscaglia F, Fili S, D’Errico-Griogioni A, Vasuri F, Tamé MR, Andreone P, Boni P, Gianstefani A, Bolondi L. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis 2009; 41: 217-225 [PMID: 18672413 DOI: 10.1016/j.dld.2008.06.009]
6 Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 Suppl 2: S36-S44 [PMID: 18825724 DOI: 10.1002/lt.21646]
7 Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, Loinaz C, Gigou M, Burra P, Barkholt L, Esteban R, Bizollon T, Lerut J, Minello-Franza A, Bernard PH, Nachbaur K, Botta-Fridlund D, Bismuth H, Schalm SW, Samuel D. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUCRHEP) Group. Gastroenterology 1999; 117: 619-625 [PMID: 10464137 DOI: 10.1016/S0016-5085(99)70454-3]
8 Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-S18 [PMID: 12562293 DOI: 10.1016/j.jttrs.2002.35781]
9 Fattovich G, Giustina G, Degas F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thom- Has H, Nijapau C, Casarin C, Bonetti P, Fuschip P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472 [PMID: 9024300 DOI: 10.1016/j.gast.1997.v112.pm9024300]
10 Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684 [PMID: 10782918 DOI: 10.1016/S0168-8278(00)80463-8]
11 Pruthi J, Medikff KA, Ersanson KT, Donovan JA, Yoshida EM, Ezb-SR, Steinbrocher UP, Fong TL. Assessment of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811-815 [PMID: 11552217 DOI: 10.1016/j.lts.2001.27084]
12 Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896 [PMID: 11910340 DOI: 10.1016/j.gastro.2002.32418]
13 Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill...
JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820 [PMID: 8956457 DOI: 10.1056/NEJM199606203341102]

14 Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M, Mir J, Berenguer J. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-256 [PMID: 9862874 DOI: 10.1002/hep.10290122]

15 Firpi RJ, Abdelmalek MF, Soldevilla-Pico C, Cabrera R, Shuster JJ, Theriaque D, Reed AJ, Hemming AW, Liu C, Crawford JM, Nelson DR. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplant 2004; 10: 1240-1247 [PMID: 15376304 DOI: 10.1002/lt.20238]

16 Neumann UP, Berg T, Bahra M, Seefhoer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 850-856 [PMID: 15519657 DOI: 10.1016/j.jhep.2004.06.029]

17 Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-1182 [PMID: 9603164 DOI: 10.1097/00007890-199805150-00006]

18 Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6: 44-53 [PMID: 10648577 DOI: 10.1016/S1527-6465(00)80032-5]

19 Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, Brooks BK, Levy MF, Gonwa TA, Klintmalm GB. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553-561 [PMID: 10980053 DOI: 10.1013/jlt.2000.9741]

20 Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papanephotidis GV, Sabin CA, Rolando N, Davies S, Dhillon AP, Griffiths P, Emery V, Patch DW, Davidson BR, Rolles K, Burroughs AK. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-395 [PMID: 15776454 DOI: 10.1002/lt.20344]

21 Davison SE, Pernow BC, O’Grady JG, Aldis PM, Chaggar K, Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-157 [PMID: 1988336 DOI: 10.1002/hep.180130122]

22 Zylberberg H, Carnot F, Mamzer MF, Blanco G, Legendre C, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158-160 [PMID: 9000679 DOI: 10.1097/00007890-199701150-00029]

23 Narang TK, Ahmed A, Kamal A. Donor diabetes mellitus is an independent risk factor for graft loss in HCV positive but not HCV negative liver transplant recipients. Dig Dis Sci 2013; 58: 574-578 [PMID: 22923339 DOI: 10.1007/s10620-012-2345-7]

24 Beller LS, Burroughs AK, Burra P, Albores-A�, Sanzakakis D, Cammã C, De Carls L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Bonissegna S, Davidson BR, Rolles K, Pinzello G. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733-740 [PMID: 17370330 DOI: 10.1011/jtransproceed.2011.02.034]

25 Duarte-Rojo A, Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK, McHutchison JG, Tillman HL, Porteucha JJ, Charlton MR. Interleukin-28B and fibrosing cholestatic hepatitis in post-transplant hepatitis C: a case-control study and literature review. Liver Transpl 2013; 19: 1311-1317 [PMID: 24039107 DOI: 10.1002/lt.23733]

26 Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol 2008; 1: 396-402 [PMID: 1875628]

27 Zeybek A, Bishop GA, Bowen DG, Gleenon MM, Guneys P, Painter DM, McCaughan GW. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002; 8: 292-301 [PMID: 11901576 DOI: 10.1053/jt.2002.31655]

28 Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008; 14 Suppl 2: S27-S35 [PMID: 18825723 DOI: 10.1002/lt.21644]
Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, Furlini G, Bellusci R, Roda E, Cavallari A. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884-888. DOI: 10.1011/j caratteristiche dellesulo.36402860.10.1053/jlt.2002.36401

Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722. DOI: 10.1016/j.jhep.2006.01.005

Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchiatti A, D'Errico A, Guido M, Merenda R, Neri D, Zanello M, Giannini FM, Grazi GL, Cillo U, Pinna DA. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47: 793-798. DOI: 10.1016/j.jhep.2007.07.023

Klintgmb GL, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinikhabwala M, Koneru B, Abecasis M, Millis J, Jennings LW, Fasola GA. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-1403. DOI: 10.1002/lt.22417

Walter T, Dumortier J, Guillaud O, Hervieu V, Scoazec JY, Boillot O. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under anti-viral therapy: A retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007; 13: 294-301. DOI: 10.1002/lt.21200

Ishii N, Watabsi K, Hishiki T, Goto K, Inoue D, Hijikata M, Kato N, Kanematsu T, Ishii N, Eguchi K. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292-298. DOI: 18366351.DOI: 10.1002/lt.21358

Villamiel L, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Ross M, Lake J, Munn S, Mühlbacher F, Leonardi L, Cillo U. Long-term outcomes in liver transplant patients with hepatitis C infection receiving tacrolimus or cyclosporine. Transplant Proc 2006; 38: 2964-2967. DOI: 17128275.DOI: 10.1016/j.tranproc.2006.08.131

Zervos VA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, Pinna AD, Kato T, Miller J, Reddy KR, Izakis AG. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 1998; 65: 1044-1046. DOI: 9583686.DOI: 10.1097/00007890-199804270-00006

Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantissi G, Villamiel F, Cillo U, Claiven PA, Klintgmb GL, Otto G, Pollard S, McCormick PA. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LSTRS) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12: 1464-1472. DOI: 17004259.DOI: 10.1002/0820

O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance for 3 years. Am J Transplant 2007; 7: 137-141. DOI: 10.1111/j.1604-6143.2007.01576.x

Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, Moya A, Pareja E, Montalva E, Yago M, de Juan M, Mir J, Prieto M. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-1209. DOI: 21068701.DOI: 10.1097/TP.0b013e3181f93a6

Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-796. DOI: 17050028.DOI: 10.1016/j.jhep.2006.07.030

Carrón JA, Martinez-Bauer E, Crespo G, Ramirez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-728. DOI: 19217183.DOI: 10.1016/j.jhep.2008.11.015

Roche B, Samuel D. Antiviral therapy in HCV-infected cirrhosis awaiting liver transplantation: A costly strategy for mixed virological results. J Hepatol 2009; 50: 652-654. DOI: 19231019.DOI: 10.1016/j.jhep.2009.01.008

Hézode C, Fontaine H, Durival C, Larrey D, Zoulia F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe J, Alicr L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucardime D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441. DOI: 23669289.DOI: 10.1016/j.jhep.2013.04.035

Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribeiro ML, Coppari J, Romito R, Burgio L, Zucchini N, Urbanek T, Bonino F. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplantation 2001; 717: 722-728. DOI: 16487616.DOI: 10.1016/j.jhep.2008.11.015

Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N. Preemptive therapy for hepatitis C virus after liver transplantation with early interferon and ribavirin treatment. Transplantation 2001; 73: 1355-1357. DOI: 11267325.DOI: 10.1002/soti.20050258-2

Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J, Lopez-Talavera JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298. DOI: 15660392.DOI: 10.1002/hep.20560

Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124. DOI: 15636619.DOI: 10.1111/j.1604-6143.2004.00648.x

Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-538. DOI: 21506241.DOI: 10.1011/j.tranproc.2010.05.020

Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemoi, C, Kohard M, Reyes M, Chevaillier M, Ducert F, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Treno C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2005; 124: 642-650. DOI: 12612905.DOI: 10.1053/gast.2003.50095

Dumortier J, Scoazec JY, Chevaillier F, Boillot O. Treatment...
of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674 [PMID: 15039864 DOI: 10.1016/j.jhep.2003.12.032]

88 Rodríguez-Luna H, Khatib A, Sharma P, De Petris G, Williams J W, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-194 [PMID: 14742979 DOI: 10.1097/01.TP.00000481.14514.BB]

89 Ross AS, Bhan AK, Aqel BA, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil Rodríguez-Luna H, Khatib A, Sharma P, De Petris G, Williams J W, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-194 [PMID: 14742979 DOI: 10.1097/01.TP.00000481.14514.BB]

90 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

91 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil

92 Comas M, Grazi GL, Cucchiatti A, Vetrone G, Ravaolmi O, Ercolini G, Morelli MC, Pisciglia F, Tame M, Pinna AD. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transplant 2009; 15: 782-789 [PMID: 19562715 DOI: 10.1001/jt.21760]

93 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

94 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil

95 ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334-340 [PMID: 21659948]

96 Comas M, Grazi GL, Cucchiatti A, Vetrone G, Ravaolmi O, Ercolini G, Morelli MC, Pisciglia F, Tame M, Pinna AD. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transplant 2009; 15: 782-789 [PMID: 19562715 DOI: 10.1001/jt.21760]

97 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

98 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil

99 ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334-340 [PMID: 21659948]

100 ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334-340 [PMID: 21659948]

101 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

102 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil

103 ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334-340 [PMID: 21659948]

104 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

105 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil

106 ReViS-TC Study Group. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334-340 [PMID: 21659948]

107 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

108 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil

109 Gavrilov B, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443]

110 Werner CR, Egelters EM, Pater WA, Zuckerman AJ, Wiersinga WM, Koning L, Murphy JL, Henry J, Bhan AK, Pascual M, Thiim M, Benedict Cosimi B, Dumortier J, Guillaud O, Hervieu V, Paliard P, Schuppan D, Müller V, Schellerer V, Tannapfel A, Khatib A, Sharma P, De Petris G, Wil
recent hepatocitis C after liver transplantation in nonre-sponders: biochemical, virological, and histological impact. Liver Transpl 2009; 15: 54-63 [PMID: 19109834 DOI: 10.1002/lt.21652]

112 Nair S, Khan S, Loss G, Eason J, Blazek J, Lipscomb J, Mason A. Treatment of recurrent hepatocitis C in liver transplant recipients: is there any histologic benefit? Liver Transpl 2003; 9: 354-359 [PMID: 12682885 DOI: 10.1053/jlts.2003.50068]

113 Berenguer M, Palau A, Fernandez A, Benilloc S, Aguiller A, Prieto M, Rayon JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatocitis C. Liver Transpl 2006; 12: 1067-1076 [PMID: 16622844 DOI: 10.1002/lt.20737]

114 Fernandez I, Menec JC, Colina F, Garcia I, Munoz R, Castellano G, Fuertes A, Abradeo M, Lumbrares C, Moreno E, Solis-Herruoz JA. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatocitis C after liver transplantation. Liver Transpl 2006; 12: 1805-1812 [PMID: 17133585 DOI: 10.1002/lt.20893]

115 Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhau s R, Neuhaus P. Treatment of patients with recurrent hepatocitis C after liver transplantation with peginterferon alfa-2b plus ribavirin. Transplantation 2006; 82: 43-47 [PMID: 16861940 DOI: 10.1097/01.TP.0000225827.18034.be]

116 Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garcia Z, Moreno A, Boullona-Grata EF, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Hepatocitis C recurrence after liver transplantation: Viral and histologic response to full-dose Peg-interferon and ribavirin. Am J Transplant 2006; 6: 2348-2355 [PMID: 16869810 DOI: 10.1111/j.1600-6143.2006.01470.x]

117 Bertuzzo VR, Cescon M, Morelli MC, Di Gioia P, Tamé M, Lorenzini S, Andreone P, Ercolani G, Del Gaudio M, Ravaol G, Mucciti A, Dazzi A, D’Errico-Grigioni A, Pinna AD. Long-term antiviral treatment for recurrent hepatocitis C after liver transplantation. Dig Liver Dis 2012; 44: 861-867 [PMID: 22819676 DOI: 10.1016/j.dld.2012.06.013]

118 Berenguer M, Prieto M, Palau A, Rayon JM, Carrasco D, Juan F, Lopez-Labrador FX, Moreno R, Mij R, Berenguer J. Severe recurrent hepatocitis C after liver retransplantation for hepatocitis C-related graft cirrhosis. Liver Transpl 2003; 9: 228-235 [PMID: 12691908 DOI: 10.1053/ljtl.2003.50029]

119 Roayaie S, Schiano TD, Thung SN, Emre SH, Fishbein TM, Miller CM, Schwartz ME. Results of retransplantation for recurrent hepatocitis C. Hepatology 2002; 36: 1428-1436 [PMID: 14647054 DOI: 10.1001/hep.2003.09.010]

120 Yoo HY, Maheshwari A, Thuluvath P. Retransplantation of liver: primary graft nonfunction and hepatocitis C virus are associated with worse outcome. Liver Transpl 2003; 9: 897-904 [PMID: 12942450 DOI: 10.1053/jlts.2003.50176]

121 Neff GW, O’Brien CB, Nery J, Shire NJ, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatocitis C virus are associated with worse outcome. Liver Transpl 2003; 9: 897-904 [PMID: 12942450 DOI: 10.1053/jlts.2003.50176]

122 Yoo HY, Maheshwari A, Thuluvath P. Retransplantation of liver: primary graft nonfunction and hepatocitis C virus are associated with worse outcome. Liver Transpl 2003; 9: 897-904 [PMID: 12942450 DOI: 10.1053/jlts.2003.50176]

123 Yao FY, Saab S, Bass NM, Hirsch T, Ly D, Tarraut N, Lazar AA, Bachetti P, Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004; 39: 230-238 [PMID: 14986010 DOI: 10.1002/htj.20128]

124 Bellido CB, Martinez JM, Gomez LM, Artacho G, Diez-Canedo JS, Pulido LB, Acevedo JM, Bravo MA. Indications for and survival after liver retransplantation. Transplant Proc 2010; 42: 637-640 [PMID: 20304211 DOI: 10.1016/j.transproceed.2010.02.017]

125 Andres A, Gerstel I, Bencuercse C, Asthana S, Merani S, Majno P, Berney T, Moro P, Kneteman N, Menthia G, Toso C. A score predicting survival after liver retransplantation for hepatocitis C virus cirrhosis. Transplantation 2012; 93: 717-722 [PMID: 22627157 DOI: 10.1097/TP .0b013e318246b893]
136 **Sainz B**, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Up-richard SL. Identification of the Niemann-Pick CI-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. *Nat Med* 2012; 18: 281-285 [PMID: 2231557 DOI: 10.1038/nm.2581]

137 **Ashfaq UA**, Qasim M, Yousaf MZ, Awan MT, Jahan S. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies. *J Transl Med* 2011; 9: 194 [PMID: 22074322 DOI: 10.1186/1479-5876-9-194]

138 **Deuffic-Burban S**, Mathurin P, Rosa I, Bouvier AM, Cannesson A, Mourad A, Canva V, Louvet A, Deltenre P, Boleslawski E, Truant S, Pruvot FR, Dharancy S. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. *Dig Liver Dis* 2014; 46: 157-163 [PMID: 24119483 DOI: 10.1016/j.dld.2013.08.137]

139 **Deuffic-Burban S**, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P. Predicted effects of treatment for HCV infection vary among European countries. *Gastroenterology* 2012; 143: 974-85.e14 [PMID: 22863764 DOI: 10.1053/j.gastro.2012.05.054]

P- Reviewer: Berg CP, Chau CY  S- Editor: Qi Y
L- Editor: Webster JR  E- Editor: Zhang DN
